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The development of immunosuppressive drugs to control adaptive immune responses has
led to the success of transplantation as a therapy for end-stage organ failure. However,
these agents are largely ineffective in suppressing components of the innate immune sys-
tem.This distinction has gained in clinical signiﬁcance as mounting evidence now indicates
that innate immune responses play important roles in the acute and chronic rejection of
whole organ allografts. For instance, whereas clinical interest in natural killer (NK) cells was
once largely conﬁned to the ﬁeld of bone marrow transplantation, recent ﬁndings suggest
that these cells can also participate in the acute rejection of cardiac allografts and prevent
tolerance induction. Stimulation ofToll-like receptors (TLRs), another important component
of innate immunity, by endogenous ligands released in response to ischemia/reperfusion
is now known to cause an inﬂammatory milieu favorable to graft rejection and abrogation
of tolerance. Emerging data suggest that activation of complement is linked to acute rejec-
tion and interferes with tolerance. In summary, the conventional wisdom that the innate
immune system is of little importance in whole organ transplantation is no longer tenable.
The addition of strategies that target TLRs, NK cells, complement, and other components
of the innate immune system will be necessary to eventually achieve long-term tolerance
to human allograft recipients.
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INTRODUCTION
Colossal advances over the past decades with the use of immuno-
suppressive drugs have signiﬁcantly enhanced the early survival of
allogeneic organs and tissues in clinical transplantation (Cecka,
1998; Opelz et al., 1999; Opelz and Dohler, 2008a,b). Never-
theless, longer term success rates remain disappointing due to
treatment-related complications and chronic allograft rejection, a
process characterized by perivascular inﬂammation, tissue ﬁbro-
sis, and luminal occlusion of graft blood vessels (Hayry et al.,
1993; Hosenpud et al., 1997; Russell et al., 1997; Kean et al., 2006).
This stresses the need for the development of selective immune-
therapies designed to achieve transplantation tolerance deﬁned
as indeﬁnite graft survival in the absence of immunosuppres-
sion and graft vasculopathy (Billingham et al., 1953; Owen et al.,
1954). While tolerance to some solid organ allografts has been
accomplished in several experimental rodent models, consistent
establishment of tolerance in patients still remains an elusive goal.
It is ﬁrmly established that the potent adaptive immune responses
initiated by pro-inﬂammatory T cells activated via direct and indi-
rect pathways in the host’s secondary lymphoid organs are both
necessary and sufﬁcient to ensure acute rejection of most allo-
grafts (Benichou et al., 1992, 1999; Fangmann et al., 1993; Sayegh
et al., 1994; Auchincloss and Sultan, 1996; Lee et al., 1997; Waaga
et al., 1997). At the same time, it is now ﬁrmly established that
the presence of alloreactive memory T cells or donor-speciﬁc anti-
bodies in so-called sensitized recipients represents a formidable
barrier to transplant tolerance induction (Adams et al., 2003a; Tay-
lor et al., 2004;Valujskikh, 2006; Koyama et al., 2007;Weaver et al.,
2009; Nadazdin et al., 2010, 2011; Yamada et al., 2011). Indeed,
much effort is currently devoted to the elimination or inhibition
of donor-speciﬁc memory T cells (TMEM) in primates, which,
unlike laboratory mice, display high frequencies of alloreactive
TMEM prior to transplantation (Nadazdin et al., 2010, 2011).
Altogether, themajority of transplant immunologists have focused
their efforts on the deletion and/or inactivation of alloreactive T
and B cells, pre-transplantation. On the other hand, recent studies
haveprovenbeyonddoubt that innate immunity is also an essential
element of both acute and chronic rejection of allo- and xenografts
(LaRosa et al., 2007;Alegre et al., 2008a,b;Alegre and Chong, 2009;
Li, 2010; Goldstein, 2011; Murphy et al., 2011). Innate immune
responses are initiated as a consequence of reperfusion injury,
inﬂammation, tissue damage, and presumably microbial infec-
tions occurring at the time of transplantation (Figure 1). Different
cells of the innate immune system can contribute to the rejection
process both directly via secretion of soluble factors and destruc-
tion of donor grafted cells as well as indirectly by initiating or
enhancing adaptive immune alloresponses while impairing the
activation/expansion of protective regulatory T cells (Figure 1). At
the same time, there is increasing evidence suggesting that different
cells and molecules associated with innate immunity can hinder
tolerance induction to allografts and xenografts (LaRosa et al.,
2007; Alegre et al., 2008b; Wang et al., 2008; Murphy et al., 2011).
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FIGURE 1 | Leukocytes and major cytokines involved in the innate
immune response after allotransplantation.
At ﬁrst glance, it can be speculated that all cells and molecules
mediating graft rejection can potentially prevent tolerogenesis.
However, immune rejection and tolerance resistance do not nec-
essarily involve the same mechanisms and these two processes are
likely to differ in nature and magnitude. This article reviews some
of the mechanisms by which innate immunity can interfere with
establishment or maintenance of tolerance to allogeneic trans-
plants, an issue that is essential to the design of novel tolerance
strategies in transplantation.
RECEPTORS AND SOLUBLE MEDIATORS OF THE INNATE
IMMUNE SYSTEM
TOLL-LIKE RECEPTORS
Lymphocytes recognize exquisitely a vast array of molecularmotifs
via their antigen receptors generated through somatic recombina-
tion of gene segments during development. In contrast, cells of
the innate immune system interact with a few conserved mol-
ecules expressed by microorganisms referred to as pathogen-
associated molecular patterns (PAMPs; Medzhitov, 2001;
Medzhitov and Janeway, 2002). Among these pattern-recognition
receptors (PRRs; Medzhitov, 2001; Elmaagacli et al., 2006;
Uematsu and Akira, 2007), the Toll-like receptors (TLRs) have
been extensively characterized and studied for their role in the ini-
tiation and ampliﬁcation of innate immune responses (Iwasaki
and Medzhitov, 2004; Pasare and Medzhitov, 2005). In addi-
tion, there is increasing evidence that tissue injury is associated
with the delivery of signal delivered through TLRs by so-called
damage-associated molecular patterns or DAMPs (Alegre et al.,
2008a,b).
Until now, 10 different TLRs have been identiﬁed in humans
(13 in mice), including TLRs 1, 2, 4, 5, and 6 expressed on the cell
surface and TLRs 3, 7, 8, and 9 found in endosomal compartments
(Rehli, 2002; Akira and Takeda, 2004; Akira et al., 2006). TLR1
is ubiquitously expressed while the other TLRs exhibit different
expression patterns depending upon the type of leukocyte (Muzio
et al., 2000; McCurdy et al., 2001; Hornung et al., 2002; Zarember
and Godowski, 2002; Bourke et al., 2003; Caramalho et al., 2003;
Hayashi et al., 2003; Nagase et al., 2003; Hart et al., 2005; Liu et al.,
2006). On the other hand, all TLRs are expressed by epithelial cells
while TLRs 5–10 are found in endothelial cells (Frantz et al., 1999)
and other graft parenchymal cells depending upon the nature of
the organ. All TLRs transduce their signal though the adapter-
protein MyD88 (Barton and Medzhitov, 2003; Akira and Takeda,
2004) with the exception of TLR3 which uses the Toll-IL-1R (TIR)
inducing IFNβ protein, TRIF (Frantz et al., 1999, 2001; Faure et al.,
2000; Tsuboi et al., 2002; Harada et al., 2003; Mempel et al., 2003;
Sukkar et al., 2006). TLR4 uses both MyD88 and TRIF during cell
activation (Sakaguchi et al., 2003; Goriely et al., 2006; Molle et al.,
2007). While the primary functions of TLRs is to ensure early
detection of microbes and their products, these receptors have
been shown to recognize autologous molecules expressed during
the course of inﬂammatory processes such as nucleic acids released
by necrotic cells, products of degraded extracellular matrices, heat
shock proteins (HSP60 and HSP70 via TLR2 and TLR4; Asea,
2008), high mobility group box chromosomal protein 1 (TLRs 2,
4, and 9), and hyaluronan (TLR signaling via TIRAP; Mollen et al.,
2006; Tesar et al., 2006; Ivanov et al., 2007; Kanzler et al., 2007; Tian
et al., 2007). Transplant surgical procedures, which are associated
with tissue damage and reperfusion injury trigger inﬂammatory
reactions engaging the delivery of signals through TLRs and sub-
sequent initiation of potent innate immune responses at the graft
site. In addition,maturation and activation of donor and recipient
dendritic cells (DCs) and other cells of the innate immune system
via TLR ligation is essential to their ability to initiate and amplify
adaptive immunity. This process involves the secretion of pro-
inﬂammatory cytokines and chemokines (Shimamoto et al., 2006;
Wu et al., 2007a) and subsequent activation of antigen processing
pathways and the expressionof costimulation andMHCmolecules
by APCs involved in antigen presentation to T and B lympho-
cytes (Bluestone, 1996). Therefore, TLRs are considered to be an
essential link between innate and adaptive immunity. These obser-
vations suggest that TLRs play a key role in the initiation of innate
immune responses and the recruitment and activation of alloreac-
tive lymphocytes associated with allograft rejection. In support of
this view, absence of MyD88 adaptor-protein in both donor and
recipientmice has led to acceptance of minor antigen-mismatched
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skin allografts and prolonged survival of fully allogeneic heart and
skin transplants (Goldstein et al., 2003; Tesar et al., 2004). Further-
more, combined deﬁciencies of MyD88 and TRIF and expressions
in donors have been shown to signiﬁcantly extend the survival of
MHC-mismatched allografts. At the same time, there is accumu-
lating evidence showing that TLR-mediated responses can hinder
tolerance induction to allotransplants. First, it has been reported
that long-term survival of skin allografts can be achieved in mice
through costimulation blockade but only upon inhibition of TLR
signaling in both donors and recipient mice (Chen et al., 2006;
Walker et al., 2006). In another study, tolerance to cardiac allografts
induced via donor-speciﬁc transfusion (DST) combinedwith anti-
CD40L mAb-mediated costimulation blockade was prevented by
injection of the TLR9 agonist, CpG as well as the TLR2 ligand,
Pam3CysK. In this study, tolerance resistance was attributed to
increased γIFN production and inhibition of graft inﬁltration by
regulatory T cells (Chen et al., 2006). Similarly, administration
of CpG, LPS, or poly I:C which activate TLR 9, 4, and 3, respec-
tively, prevented tolerance induction to skin allografts induced via
DST+ anti-CD40L mAbs. In this model, it was observed that TLR
engagementprevented thedeletionof someeffector donor-speciﬁc
CD8+ T cells (Thornley et al., 2006), a process relying on type
I interferon production (Thornley et al., 2007). Finally, Turka’s
group recently reported that spontaneous tolerance to MHC class
II-mismatched skinheart allografts aswell as long-termacceptance
of skin allografts mediated via anti-CD40L mAb and rapamycin
cotreatment in the B6-bm12 mouse combination were both pre-
vented by CpG administration (Porrett et al., 2008). In this study,
prevention of tolerance was dependent on IL-12 production by
APCs, which is critical to the differentiation of pro-inﬂammatory
type 1 (Th1/CT1) immunity. Therefore, engagement of certain
TLRs at the time of transplantation can hinder tolerance induction
to allografts via concomitant enhancement of pro-inﬂammatory
T cell responses and impairment of regulatory T cell functions.
INFLAMMATORY CYTOKINES
Certain pro-inﬂammatory cytokines produced by cells of the
innate immune systemcanprevent tolerance induction to alloanti-
gens or abrogate established tolerance of an allograft. For instance,
IL-6 and TNFα deﬁciency has been shown to render mice suscep-
tible to transplant tolerance induction via costimulation blockade
(Walker et al., 2006; Shen and Goldstein, 2009). Apparently, IL-
6 and TNFα contributed to prevent tolerogenesis by enhancing
pro-inﬂammatory immunity while rendering T cells resistant to
suppression by Tregs (Walker et al., 2006; Shen and Goldstein,
2009). Likewise, type 1 interferons have been shown to confer tol-
erance resistance of skin allografts mediated via anti-CD154 mAb
treatment inmousemodels (Thornley et al., 2007). Tolerance resis-
tance to vascularized allografts induced via costimulationblockade
following Listeria monocytogenes infection has been shown to rely
on IFN α and β productions. In another study, evidence was
provided that IL-6 could prevent transplant tolerance to cardiac
allografts induced through the disruption of CD40/CD40L inter-
actions, by promoting the differentiation and activation of CD8+
TH17 cells (Burrell et al., 2008).
IL-1α is produced constitutively and at low levels by many
epithelial cells but it is found in substantial amounts in the
epidermis where its secretion by keratinocytes is thought to play a
key role in the immune defense against microorganisms (Palmer
et al., 2007; Arend et al., 2008; Dinarello, 2009; Gabay et al.,
2010). In addition, during inﬂammation and sepsis, activated
macrophages, and polymorphonuclear neutrophils (PMNs) pro-
duce large amounts of IL-1αwhich is known to cause smoothmus-
cle cell proliferation, secretion of TNFα by endothelial cells, the
synthesis of acute phase proteins, and amplify antigen-speciﬁc and
alloreactive T and B cell responses (Rao et al., 2007, 2008; Rao and
Pober, 2008; Dinarello, 2011a). IL-1β, also called lymphocyte acti-
vating factor (LAF), is primarily released by activatedmacrophages
during inﬂammation (Rao et al., 2007;Netea et al., 2010;Dinarello,
2011b,c). It is involved in a variety of cellular activities, including
cell proliferation, differentiation, and apoptosis. The induction
of cyclooxygenase 2 (PTGS2/COX2) by this cytokine in various
tissues including the central nervous system (CNS) is found to
contribute to hypersensitivity reactions and pain. IL-1α and β
play a role in mediating acute inﬂammation during ischemia–
reperfusion (I/R) injury after transplantation (Suzuki et al., 2001).
Ischemia and hyperoxia/anoxia both contributes to the release
of IL-1 by macrophages (from the NALP-3 inﬂammasome), a
process leading to both necrosis and apoptosis of transplanted
cells, neutrophilic inﬂammation and initiation, and ampliﬁca-
tion of adaptive immune responses (Wanderer, 2010). Indeed,
it has been shown that overexpression of IL-1R antagonist (IL-
1Ra) can confer cardioprotection against I/R injury associated
with reduction in cardiomyocyte apoptosis and decrease of neu-
trophil inﬁltration and myocardial myeloperoxidase activity in
heart-transplanted rats (Suzuki et al., 2001).
There are a few reports showing that IL-1 can prevent toler-
ance induction to allografts. IL-1β is known to contribute to the
breakdown of self-tolerance to pancreatic autoantigens resulting
in type 1 diabetes in NOD mice (Bertin-Maghit et al., 2011). This
effect is mediated via both induction of TH17 autoimmunity and
concomitant impairment of Treg differentiation and functions.
Likewise, it has been shown that IL-1 can prevent the induction
of tolerance to islet allografts (Sandberg et al., 1993). This is sup-
ported by studies showing that continuous infusion of diabetic
mice with an IL-1 receptor antagonist (IL-1Ra) can restore nor-
moglycemia and facilitate tolerance to islet allografts (Sandberg
et al., 1993). Similarly,alpha-1 anti-trypsin therapy (AAT)has been
shown to promote donor-speciﬁc tolerance to islet allografts in
mice via a process relying on the presence of immatureDCs (iDCs)
andTregs in the graft associatedwith the presence of IL-1Ra (Lewis
et al., 2008; Shahaf et al., 2011). In another set of studies by Holan
(1988), it was observed that transplantation tolerance induced via
inoculation of newborn mice with semi-allogeneic hematopoietic
cells was abolished via administration of IL-1 given at the time
of placement of skin allografts (Holan, 1988). Finally, a series of
studies from Dana and Streilein’s groups have shown that IL-1Ra-
based therapy can restore anterior chamber-associated immune
deviation (ACAID) type tolerance associated with immune priv-
ilege in the eye and acceptance of allogeneic corneal transplants
(Dana et al., 1997, 1998; Yamada et al., 1998, 2000; Dekaris et al.,
1999). Interestingly, IL-1Ra treatment in this model was shown
to abolish donor-speciﬁc DTH, reduce corneal graft inﬁltration
by recipient Langerhans cells and abrogate second set rejection of
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skin allografts suggesting an impaired antigen presentation and a
lack of systemic priming of alloreactive T cells through the indi-
rect allorecognition pathway in draining lymph nodes (Dana et al.,
1997, 1998; Yamada et al., 1998, 2000; Dekaris et al., 1999).
CHEMOKINES
Chemokines represent an extensive family of proteins whose
function was initially associated with leukocyte chemotaxis. It
is now clear that these molecules are also involved in a variety
of biological processes including angiogenesis and hematopoiesis
(Sallusto et al., 2000). There is ample evidence showing that
chemokines play a key role in the initiation of alloantigen-
dependent and alloantigen-independent reactions associated with
transplant injury as well as acute and chronic rejection of allo-
grafts (DeVries et al., 2003). Likewise, many studies have shown
that absence (KO mouse models) or in vivo neutralization of var-
ious chemokines or chemokine receptors, usually combined with
short-termor suboptimal calcineurin inhibitory treatment, results
in prolonged and sometimes indeﬁnite survival of allografts in
animal models (Gao et al., 2000, 2001; Hancock et al., 2000a,b; Fis-
chereder et al., 2001; Abdi et al., 2002). These observations suggest
that chemokine release as well as leukocyte activation and migra-
tion following chemokine receptor signaling should represent a
barrier to transplant tolerance induction and/or maintenance. On
the other hand, a number of chemokines have been associatedwith
Treg activation and graft inﬁltration and are clearly necessary for
tolerance induction in transplantation (DeVries et al., 2003).
THE COMPLEMENT SYSTEM
The complement system is comprised of a variety of small proteins
including serum proteins, serosal proteins, and cell surface recep-
tors (over 25proteins andprotein fragments,5%of serumglobulin
fraction) present in the blood, generally synthesized by the liver,
and normally circulating as inactive precursors (pro-proteins;
Carroll, 1998; Kang et al., 2009).
When stimulated, the proteases in the system cleave speciﬁc
proteins and subsequent cytokine release thus initiating an ampli-
fying cascade of further cleavages. The end-result of this activation
cascade is a massive ampliﬁcation of the response and activation
of the cell-killing membrane attack complex or MAC (Peitsch and
Tschopp, 1991). Three distinct pathways are involved in comple-
ment activation: the classical pathway, the alternative pathway, and
the mannose-binding lectin pathway (Sacks et al., 2009). All of
these pathways converge on C3 whose cleavage leads to the release
of soluble C3a and C5a. It is noteworthy that while 80% of C3 is
synthesized in the liver, 20% of C3 is of extra hepatic origin and
produced by resident parenchymal cells and inﬁltrating leuko-
cytes (Naughton et al., 1996; Tang et al., 1999; Li et al., 2007).
C3a and C5a have anaphylatoxin properties and trigger directly
mast cell degranulation and increase vascular permeability and
smooth muscle contraction. Most importantly, the complement
has opsonizing and chemotactic functions in that it enhances anti-
gen phagocytosis and attracts macrophages and PMNs at the site
of inﬂammation. The complement system represents an essential
component of the inﬂammatory cascade and a major link between
innate and adaptive immunity. Likewise, there is now a body of
evidence showing that the complement is an essential element of
the inﬂammatory process as well as the immune response associ-
ated with the rejection of allogeneic transplants (Zhou et al., 2007;
Raedler et al., 2009; Raedler and Heeger, 2010; Vieyra and Heeger,
2010). First, many studies have demonstrated the contribution of
the complement to I/R injury following transplantation of a vari-
ety of organs including liver, kidney, and lungs (Weisman et al.,
1990; Ikai et al., 1996; Eppinger et al., 1997; Huang et al., 1999;
Zhou et al., 2000; Chan et al., 2006; Farrar et al., 2006; Patel et al.,
2006). Remarkably, mice lacking complement have been shown to
be unable to make high afﬁnity anti-MHC antibodies after skin
transplantation. This was due to the lack of CR2 expression, a
coreceptor that is required for antigen retention by follicular DCs
(Fearon and Carroll, 2000; Marsh et al., 2001; Pratt et al., 2002).
On the other hand, the complement plays an important role in the
antigen processing presentation by DCs and controls their ability
to activate T cells in antigen-speciﬁc fashion. Finally, elegant stud-
ies from the Heeger’s group and others have demonstrated the role
of C3 in the activation and expansion of both CD4+ and CD8+
T cells presumably by limiting antigen-induced apoptosis (Fearon
and Carroll, 2000; Marsh et al., 2001; Pratt et al., 2002; Peng et al.,
2006, 2008; Zhou et al., 2006; Lalli et al., 2008; Strainic et al., 2008).
Altogether, these studies suggest that activation of the complement
cascade following transplantation should render tolerance difﬁcult
to induce. In support of this view, it has been shown that blockade
of complement activation on DCs results in an increase of Treg
expansion and favors tolerance induction (Sacks et al., 2009).
CELLS OF THE INNATE IMMUNE SYSTEM
NK CELLS
Natural killer (NK) cells contribute to the innate immune response
through their ability to recognize and destroy foreign cells in the
absence of antigen-speciﬁc recognition (Hamerman et al., 2005).
However, although NK cells lack expression of germline-encoded
antigen receptors, they can discriminate between self- and for-
eign cells via clonotypic receptors recognizing self-MHC class I
molecules. NK cell interacting with self-MHC class I expressed
on autologous cells become inactivated while lack or suboptimal
recognition of self-MHC class I molecules (missing self phenom-
enon) on allogeneic cells results in NK cell stimulation associ-
ated with release of pro-inﬂammatory cytokines and cytotoxicity
(Karre et al., 1986; Ljunggren and Karre, 1990; Ljunggren et al.,
1990). This type of allorecognition has been shown to ensure
the destruction of skin grafts from donors lacking self-MHC
class I expression (b2m KO) as well as bone marrow transplants
from semi-allogeneic donors and parental donors to F1 recipi-
ents (hybrid resistance; Karlhofer et al., 1992, 2006). In addition,
recent evidence has been provided showing that NK cells also con-
tribute to the rejection of solid organs transplants (Oertel et al.,
2000, 2001; Kitchens et al., 2006; McNerney et al., 2006; van der
Touw and Bromberg, 2010). NK cells participate in acute allograft
rejection either directly by killing donor cells through perforin,
granzymes, FasL, and TRAIL pathways (Biron et al., 1999; Smyth
et al., 2001; Takeda et al., 2001; Trapani and Smyth, 2002) or indi-
rectly by promoting alloantigen processing and presentation by
DCs and B cells (Boehm et al., 1997) and by enhancing Type
1 T cell adaptive alloimmunity primarily though their secretion
of γIFN and TNFα (Martin-Fontecha et al., 2004; Yoshida et al.,
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2008). Furthermore, NK cells have been shown to contribute to
the rejection process by killing regulatory T cells (Roy et al., 2008).
Finally, some recent studies have demonstrated the pivotal role
of NK cells in chronic rejection of cardiac allografts through a
process involving CD4+ T cell activation (Uehara et al., 2005a,b).
Altogether, these studies support the view that NK cells represent
an essential link between innate and adaptive immune responses
leading to acute and chronic rejectionof allogeneic transplants.On
the other hand, a study from Szot et al. (2001) has demonstrated
that NK cells can also impair tolerance induction to a solid organ
transplant. In this model, injection of recipient CD28-deﬁcient
mice with anti-CD154 antibodies failed to accomplish indeﬁnite
survival of cardiac allografts. However, tolerance to heart allo-
grafts was restored upon in vivo depletion of NK cells or inhibition
of the NK activating receptor, NKGD. Apparently, NK cells acti-
vated consequently to the absence of self-MHC class I molecules
on transplanted cells could provide help (otherwise missing in
CD28KO mice) to CD8+ T cells and thereby prevented tolerance
induction (Maier et al., 2001; Kim et al., 2007).
DENDRITIC CELLS
Dendritic cells are considered as the primary link between innate
and adaptive immunity based on their ability to prime naïve T
cells owing to: (1) efﬁcient processing and presentation of anti-
gen peptides in association with self-MHC molecules and, (2) the
delivery of key costimulation signals (Steinman and Cohn, 1973;
Austyn et al., 1983, 1988; Banchereau and Steinman, 1998; Lanza-
vecchia and Sallusto, 2000, 2001; Steinman et al., 2000). Actually,
the T cell alloresponse is primarily initiated through the recogni-
tion of intact donor-MHC molecules on donor DCs inﬁltrating
the recipient’s secondary lymphoid organs (direct allorecognition;
Steinman and Witmer, 1978; Lechler and Batchelor, 1982; Larsen
et al., 1990a,b,c,d; Lechler et al., 1990; Larsen and Austyn, 1991).
The direct alloresponse is believed to represent the driving force
behind acute allograft rejection. Alternatively, some alloreactive T
cells become activated after recognition of donor peptides (MHC
and minor antigens) presented by self-MHC molecules on recip-
ient DCs (indirect allorecognition; Benichou et al., 1992, 1999;
Dalchau et al., 1992; Fangmann et al., 1992; Liu et al., 1996; Sayegh
and Carpenter, 1996). The mechanisms by which recipient DCs
acquire donor alloantigens are still unknown. The direct allore-
sponse is believed to be short-lived due to the rapid elimination
of donor DCs, while the indirect alloresponse may be perpetuated
by continuous presentation of donor peptides by recipient APCs.
While it is clear that indirect alloreactivity is sufﬁcient to trigger
vigorous rejection of skin allografts, whether this response plays a
signiﬁcant role in acute rejection of vascularized solid organ trans-
plants is still open to question (Auchincloss et al., 1993; Lee et al.,
1994, 1997; Illigens et al., 2002). On the other hand, maintenance
of indirect alloresponses via continuous presentation of allopep-
tides by recipient DCs and endothelial cells is clearly associated
with alloantibody production, chronic inﬂammation, and allo-
graft vasculopathy (Suciu-Foca et al., 1996, 1998; Shirwan, 1999;
Baker et al., 2001; Lee et al., 2001; Najaﬁan et al., 2002; Shirwan
et al., 2003; Yamada et al., 2003; Illigens et al., 2009). Finally, some
recent studies show that recipient DCs can capture donor-MHC
molecules and presumably other donor proteins from donor DCs
and endothelial through a process called trogocytosis (Joly and
Hudrisier, 2003; Aucher et al., 2008). Theoretically, presentation
of intact allo-MHC molecules by host professional APCs could
activate some alloreactive T cells, a mechanism referred to as semi-
direct allorecognition. While, it has been shown that DCs having
acquired donor-MHC molecules can activate T cells in vitro and
in vivo, the actual contribution of semi-direct alloreactivity to the
alloresponse and allograft rejection is still unknown (Herrera et al.,
2004; Smyth et al., 2006, 2007).
Dendritic cells consist of a diverse population of cells charac-
terized by a few common surface markers and some functional
characteristics (Banchereau and Steinman, 1998; Liu et al., 2009).
In addition,DC functions can differ dramatically depending upon
their degree of maturation (Steinman et al., 2003; Wilson and Vil-
ladangos, 2004). Myeloid iDCs, which have not yet encountered
antigens or become activated via PAMPs or cytokine exposure,
express low levels of MHC class II and costimulatory receptors
and are poor APCs. Presentation of alloantigens by these iDCs
has been associated with peripheral tolerance induction (Fu et al.,
1996; Dhodapkar et al., 2001; Roncarolo et al., 2001) and immune
privilege (Stein-Streilein and Streilein, 2002; Streilein et al., 2002;
Masli et al., 2006) presumably via T cell anergy (Fu et al., 1996;
Dhodapkar et al., 2001; Roncarolo et al., 2001). In contrast, DCs
(mDCS) which underwent maturation following antigen uptake
andprocessing in an inﬂammatory cytokine environment or expo-
sure to PAMPs and presumably DAMPs express high levels of
MHC class II and costimulation receptors are potent inducers of
type 1 alloimmunity after transplantation (Rogers and Lechler,
2001). Alternatively, plasmocytoid DCs (pDCs), which represent
a small population of DCs mostly located in the peripheral blood,
are thought to contribute to tolerance induction via IL-10 secre-
tion following ICOS costimulation and presumably induction of
regulatory T cell responses (Abe et al., 2005; Liu, 2005; Ochando
et al., 2006; Ito et al., 2007; Tokita et al., 2008; Matta et al., 2010).
Finally, seminal studies by Thomson and others have shown that
physical or chemicalmodiﬁcations of DCs can render them tolero-
genic (Bacci et al., 1996; Kurimoto et al., 2000; Lu and Thomson,
2002; Thomson, 2002; Morelli and Thomson, 2003; Turnquist
et al., 2007) and ensure long-term survival to allografts upon their
in vivo transfer to recipients (Lu and Thomson, 2002; Thomson,
2002; Morelli and Thomson, 2003; Turnquist et al., 2007).
Altogether, these studies emphasize that DCs represent an
essential link between innate and adaptive alloimmunity by serv-
ing as APCs for alloantigen presentation to T cells, by providing
critical costimulation signals, and by secreting cytokines both at
the site of grafting and in the host’s lymphoid tissues and organs.
At the same time, it has become evident that the role of DCs in
the alloimmune response and rejection process is extremely com-
plex and depends on many factors including the origin (recipient
or donor) of the DCs, the nature of the DCs, their level of mat-
uration, and the environment in which they become activated.
It was initially assumed that donor or recipient DCs might hin-
der tolerance induction to allografts owing to their contribution
to the priming of alloreactive T cells and the secretion of pro-
inﬂammatory cytokines. Basedupon this principle,many attempts
have been made to deplete DCs from transplanted tissues or from
the host prior to tolerance induction. Actually, DC depletion has
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led to various and sometimes opposite outcomes depending upon
the nature of the tissue transplanted, the site of graft placement,
the method utilized to induce tolerance. For instance, depletion
of different DCs from skin transplants such as Langerhans cells
or dermal DCs can lead to opposite effects on allograft rejection
(Bobr et al., 2010; Igyarto and Kaplan, 2010; Igyarto et al., 2011).
On the overall,most studies showed that absence of DCs, either
from recipients or donors in studies using CD11C KO mice, graft
parking protocols, or antibody-mediated cell depletion, not only
regularly failed to signiﬁcantly prolong graft survival but it often
prevented tolerance induction. This further supports the view that
DCs are necessary for antigen presentation during tolerogenesis
via their ability to trigger some regulatory mechanisms resulting
in graft protection. Further studies will be needed to discriminate
between the DCs, which promote or hinder tolerance to allografts
and the mechanisms by which they determine the fate of regu-
latory T cell responses. Gaining insights into these questions will
be necessary to delete or inactivate selectively the DCs associated
with tolerance resistance in transplantation.
GRANULOCYTES, MASTOCYTES, AND MONOCYTES/MACROPHAGES
Granulocytes,mastocytes, and monocytes/macrophages are tradi-
tionally considered as key players in both early innate alloimmune
response and in the actual destruction of donor cells after trans-
plantation. However, the mechanisms by which they contribute to
alloimmunity and the actual nature of their contribution to allo-
graft rejection have not been thoroughly investigated. Likewise,
little is known regarding the impact of these cells in transplanta-
tion tolerance. This section reviews some of the few studies that
have tackled these questions.
Granulocytes are the most abundant leukocytes in the blood
of mammals and an essential part of the innate immune sys-
tem. Among them, PMNs migrate within hours to the site of
acute inﬂammation after transplantation following chemical sig-
nals such as IL-8, C5a, and Leukotriene B4 in a process called
chemotaxis. However, they survive only 1–3 days at the graft site
where they undergo degranulation and release reactive oxygen
species (ROS), a process involving the activation of NADPH oxi-
dase and the production of superoxide anions and other highly
reactive oxygen metabolites which cause tissue damage (Jaeschke
et al., 1990). There is ample evidence showing that PMNs con-
tribute to donor tissue destruction and graft rejection in skin
transplantation, solid organ transplantation, and bone marrow
transplantation (Buonocore et al., 2004; Surquin et al., 2005).
Studies from the Fairchild’s group have demonstrated that Abs
directed to KC/CXCL1 can prolong cardiac allograft survival by
preventing PMNs from graft inﬁltrating the graft (Morita et al.,
2001; LaRosa et al., 2007). Additionally, the potential role of PMNs
in the prevention of tolerance induction has been examined in two
recent studies, only. First, it has been reported that peritransplant
elimination of PMNs facilitated tolerance to fullymismatched car-
diac allografts induced via costimulation blockade (El-Sawy et al.,
2005; Mollen et al., 2006; LaRosa et al., 2007). Most interestingly,
another study from Wood’s group shows that prevention of accel-
erated rejection of skin allografts byCD8+ effectormemory T cells
could be achieved by Tregs but only following depletion of PMNs
(Jones et al., 2010). It is likely that elimination of PMNs created a
windowof opportunity that permitted Treg-mediated suppression
of graft rejection. Indeed, it well established that early activation
of pre-existing alloreactive memory T cells represents a formida-
ble barrier to tolerance induction in transplantation (Valujskikh
et al., 2002; Adams et al., 2003b; Valujskikh and Heeger, 2003;
Weaver et al., 2009; Nadazdin et al., 2011). In the model described
above, PMNs did not prevent tolerance induction directly but
indirectly by hindering the suppression of memory T cells by
Tregs. It is possible that this phenomenon represents a general
mechanism by which innate immunity prevent transplant toler-
ance induction through the potentiation of alloreactive memory
T cells. This implies that blocking innate immune responses at the
time of graft placement may impair the development of anamnes-
tic alloresponses by T cells and render allograft susceptible to
tolerogenesis by regulatory responses induced after costimula-
tion blockade or mixed hematopoietic chimerism induction, a
hypothesis that requires further investigation.
Eosinophils play a key role in the pathogenesis associated
with allergic reactions through their production of inﬂammatory
cytokines and cationic proteins (Capron and Goldman, 2001).
These cells can drive the differentiation of T cells to TH2 immu-
nity essentially via IL-4 and IL-5 cytokine release (Sanderson,
1992; Kay et al., 1997). TH2 cells that exert antagonist properties
toward their pro-inﬂammatory TH1 counterparts were initially
thought to be potential contributors to tolerogenesis in autoim-
mune diseases and transplantation (Charlton and Lafferty, 1995;
Goldman et al., 2001). Indeed, TH2 polarization has been demon-
strated to be essential in neonatal tolerance induction and in some
allotransplant models (Hancock et al., 1993; Forsthuber et al.,
1996; Onodera et al., 1997; Yamada et al., 1999; Kishimoto et al.,
2000; Waaga et al., 2001; Fedoseyeva et al., 2002). However, it
became rapidly evident that this concept is over simplistic and
that eosinophils either directly or via the activation of TH2 cells
can trigger the rejection of allografts in various models (Illigens
et al., 2009). First, there is ample evidence showing that adop-
tively transferred allospeciﬁc TH2 cells can ensure on their own
the rejection of skin and cardiac allogeneic transplants (Piccotti
et al., 1996, 1997; VanBuskirk et al., 1996; Shirwan, 1999). Second,
IL-4 and IL-5 neutralization has been shown to delay the rejection
of allografts in several models (Chan et al., 1995; Simeonovic et al.,
1997; Matesic et al., 1998; Le Moine et al., 1999; Braun et al., 2000;
Honjo et al., 2000; Goldman et al., 2001; Surquin et al., 2005).
In the B6-bm12 MHC class II classical skin graft model, rejec-
tion has been associated with a massive inﬁltration by eosinophils
(Le Moine et al., 1999; Goldman et al., 2001). IL-5 blockade
delayed the rejection process by preventing eosinophilic inﬁltra-
tion, but these allografts were ultimately rejected via a mechanism
involving PMNs (Le Moine et al., 1999; Goldman et al., 2001).
In another study from the Martinez’s group, the existence of a
non-classical pathway of liver allograft rejection was shown to
involve IL-5 and graft inﬁltrating eosinophils secreting a series of
cytotoxic mediators including eosinophil peroxidase, eosinophil-
derived neurotoxin, eosinophil cationic protein, and major basic
protein (MB; Martinez et al., 1993). In addition, a number of
studies from us and others have provided direct evidence demon-
strating that alloreactive TH2 cells activated through the indirect
allorecognition pathway can trigger chronic allograft vasculopathy
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and tissue ﬁbrosis in MHC class I-mismatched transplanted hearts
(Shirwan, 1999; Mhoyan et al., 2003; Koksoy et al., 2004; Illigens
et al., 2009). At the same time, it has been reported that, in models
in which acute rejection had been suppressed, eosinophilic graft
inﬁltration could induceﬁbrosis through their productionof TGF-
β, a key mediator of extracellular matrix remodeling (Goldman
et al., 2001). It is noteworthy that eosinophils are likely to play a
prominent role in heart and lung transplantation through their
cooperation with activated mast cells associated with IL-9 release
(Dong et al., 1999; Marone et al., 2000; Suzuki et al., 2000; Cohn
et al., 2002; Poulin et al., 2003; Steenwinckel et al., 2007). Inter-
estingly, it has been observed that depletion of CD8+ CT1 cells
and subsequent deprivation of γIFN production or IL-12 antago-
nism can result in a polarization of the T cell response toward TH2
alloimmunity and cause eosinophilic rejection of cardiac allografts
primarily driven by IL-4 and IL-5 cytokines (Noble et al., 1998;
Foucras et al., 2000; Goldman et al., 2001). This further illustrates
the complexity of the alloimmune response and the multiplicity
of the mechanisms potentially involved in the rejection process.
Indeed, as often observed in autoimmune disease models, block-
ing a known deleterious type of alloimmunity can often uncover
a different type of response also leading to allograft rejection.
Mastocytes were originally described by Paul Ehrlich in his
1878 doctoral thesis on the basis of their unique staining char-
acteristics and large granules (Alvarez-Errico et al., 2009; Barnes,
2011). These cells typically found in mucosal and connective tis-
sues (skin, lungs, and intestines) are characterized by their high
expression of IgE high afﬁnity Fc receptor (FcR) and IgG1 (in
mice) FcR. Mast cells are known for their pivotal role in immunity
against parasitic worms and their contribution to allergic reac-
tions (asthma, eczema, allergic rhinitis, and conjunctivitis). This
phenomenon is mediated mainly through degranulation of ser-
ine proteases, histamine, and serotonin and through recruitment
of eosinophils at the site of inﬂammation via the secretion of
eosinophil chemotactic factors (Alvarez-Errico et al., 2009; Barnes,
2011). Mast cells are also essential to the recruitment of T cells to
the skin and joints in autoimmune disorders including rheuma-
toid arthritis, bullous pemphigoid, and multiple sclerosis (Sayed
and Brown, 2007; Sayed et al., 2008; Schneider et al., 2010). The
role of mastocytes in allotransplantation was actually described in
seminal studies for the Voisin’s laboratory more than 40 years ago.
It was observed that non-complement ﬁxing anaphylactic IgG1
and IgE antibodies directed to donor-MHC molecules can cause
rejection of skin allografts through a process called alloantibody-
induced anaphylactic degranulation (DAAD; Daeron et al., 1972,
1975, 1980; Le Bouteiller et al., 1976; Daeron and Voisin, 1978,
1979; Benichou and Voisin, 1987). Hyperacute rejection of skin
allografts was induced through bipolar bridging of mastocytes
(through their FcR) and donor-MHC molecules on grafted cells,
a process leading to a massive anaphylactic reaction leading to
allograft rejection (Daeron et al., 1972, 1975, 1980; Le Bouteiller
et al., 1976; Daeron and Voisin, 1978, 1979). This type of “allergic
transplant rejection” discovered during the 1960s has been largely
forgotten through the years and would deserve to be revisited
using newly developed immunological models. More recently, it
has been shown that degranulating mastocytes can contribute to
allograft rejection by causing the loss of Tregs and thereby prevent
tolerance induction in a skin allograft model (deVries et al., 2009a;
Murphy et al., 2011). While Tregs can induce the maturation and
growth of mastocytes through IL-9 production, this process seems
rather to contribute to tolerance induction (Lu et al., 2006;Murphy
et al., 2011). In addition, sequestration of pro-inﬂammatory IL-6
cytokines by mastocytes through MCP6 receptors has also been
shown to promote establishment of tolerance to lung and car-
diac allografts via costimulation blockade (de Vries et al., 2009a,b,
2010; de Vries and Noelle, 2010; Murphy et al., 2011). Therefore,
the role of mastocytes in alloimmunity is more complex than ini-
tially anticipated and further studies will be required to determine
how these cells can prevent or promote tolerance induction in skin
and presumably lung transplantation.
Different macrophages derived from monocyte differentiation
are present in various tissues and organs including Kupffer cells
in the liver, microglial cells in the CNS, alveolar macrophages in
the lungs, and intraglomerular mesangial cells in the kidney (Lu
and Unanue, 1982; Unanue, 1984; Yan and Hansson, 2007; Varol
et al., 2009; Geissmann et al., 2010; Yona and Jung, 2010). These
cells are characterized by the surface expression of CD14, CD11b,
F4/80 (mice)/EMR1 (humans) as well as MAC1/3 and CD68.
Macrophages and monocytes rapidly inﬁltrate inﬂammation sites
and are typically found in large numbers within allografts (Geiss-
mann et al., 2010). Upon activation, they release large amounts
of pro-inﬂammatory cytokines such as TNFα, IL-12 IL-1, and IL-
6, which promote both innate and adaptive immune responses
(Geissmann et al., 2010).Macrophages play a key role in the induc-
tion of antibody dependent cellular cytotoxic (ADCC) reactions
leading to the phagocytosis of opsonized allogeneic target cells
(Unanue and Allen, 1986; Rocha et al., 2003; Li, 2010). During
acute inﬂammation, while PMNs are typically the ﬁrst phagocytes
inﬁltrating allografts, macrophages are usually involved in sec-
ondary stages of inﬂammation during which they remove aged
PMNs via a mechanism involving PECAM-1 (CD31) as well as
necrotic cells and cellular debris (Davies et al., 1993; Wu et al.,
2007b; Roh et al., 2010; Wu and Madri, 2010). Macrophages have
also been shown to be essential to the maintenance of chronic
inﬂammatory processes (Yan andHansson, 2007;Geissmann et al.,
2010). Likewise, some evidence has been provided suggesting that
macrophages contribute to transplant vasculopathy and ﬁbrosis
(Davies et al., 1993; Kitchens et al., 2007; Yan and Hansson, 2007;
Bani-Hani et al., 2009; Dinarello, 2011b; Kamari et al., 2011). In
addition to their role in innate immunity, macrophages process,
and present alloantigens to CD4+ T cells in a MHC class II context
thus initiating T cell-mediated responses and rejection (Beller and
Unanue, 1980; Lu et al., 1981; Unanue and Allen, 1986; Unanue,
2002; Calderon et al., 2006). Some observations indicate that, in
stable transplants, macrophages can convert otherwise harmless
lymphocytes into aggressive ones and cause rejection, thereby
controlling the cytopathic features of cellular inﬁltrates in solid
organ transplants (Li, 2010). Likewise, some studies have shown
the beneﬁcial effects of blockage of the macrophage-migration
inhibitory factor (MIF) on the pathogenesis of allografts including
the reduction of obstructive bronchiolitis after lung transplanta-
tion (Fukuyama et al., 2005; Javeed and Zhao, 2008). A study from
Heeger’s group has shown that in vivo blockade of MIF could
prevent the rejection of MHC class II KO skin allografts in mice
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mediated through the indirect allorecognition pathway (Hou et al.,
2001; Demir et al., 2003). In this model, neutralization of MIF
resulted in reducedDTH responsewhile it did not affect γIFNpro-
duction by activated T cells (Hou et al., 2001; Demir et al., 2003). It
is, however, noteworthy that different types of macrophages can be
found in kidney allografts, someof which being involved in attenu-
ationof inﬂammation,activationof Tregs, and tolerance induction
(Lu et al., 2006; Brem-Exner et al., 2008; Hutchinson et al., 2011).
Recently,macrophages have been shown tobe involved in self-non-
self discrimination, i.e., self-awareness via interaction between the
innate inhibitory receptor SIRPα expressed on their surface and
CD47. This type of recognition, which is reminiscent of the miss-
ing self-model described with NK cells, has been shown to play a
role in xenograft rejection by macrophages (Ide et al., 2007; Wang
et al., 2007; van den Berg and van der Schoot, 2008). However,
it is still unclear whether some degree of CD47 polymorphism
within a given species exists and whether it could be involved in
allorecognition.
CONCLUDING REMARKS
It is now ﬁrmly established that innate immune responses trig-
gered after transplantation as a consequence of tissue damage,
infections, and reperfusion injury are an essential element of the
inﬂammatory process leading to early rejection of allografts. In
addition, there is accumulating evidence showing the contribution
of innate immunity to chronic rejection of allogeneic transplants.
On the other hand, this review supports the view that activation of
virtually any of the cells of the innate immune system can prevent
transplant tolerance induction. This process is essentially medi-
ated via signaling of various receptors includingTLRs (viaDAMPS
and PAMPS) and the secretion of several key pro-inﬂammatory
cytokines (primarily IL-1, IL-6, TNFα, and type I interferons)
and chemokines. Activated cells of the innate immune system can
prevent tolerogenesis directly via cytokine secretion, activation of
the complement cascade, and killing of donor cells or indirectly
by promoting and amplifying deleterious inﬂammatory adaptive
immune responses while preventing the activation of protective
regulatory mechanisms. In addition, innate immune responses
can alter the immune privileged nature of the tissue transplanted
or the site of graft placement as evidenced by studies in corneal
transplantation.While, it is clear that innate immunity represents a
major barrier to tolerogenesis in allotransplantation, this phenom-
enon is presumably evenmore relevant to xenotransplantationdue
to the involvement of natural antibodies, CD47/SIRPα-mediated
interactions, and presumably many other still unknown factors.
In addition, it is likely that activation of innate type of immu-
nity can abrogate formerly established tolerance to an allograft as
suggested by some studies involving microbial infections (Miller
et al., 2008; Ahmed et al., 2011a,b). Taken together, these studies
imply that the design of future successful tolerance protocols in
transplantation will require the administration of agents capable
of suppressing innate immunity. However, a number of cells of the
innate immune system such as NK cells and DCs have been shown
to be required for transplant tolerance induction. This apparent
contradiction may be explained by the fact that different cell sub-
sets and mediators of the innate immune system are involved in
tolerance vs. rejection. Alternatively certain cells or mediators may
play opposite roles depending upon the context in which they are
activated. For instance, γIFN and IL-2 have been shown to be
essential cytokines in both rejection and tolerance of allografts. It
is likely that their dual role depends upon their concentration at
a given time point and the cells they are activating in a particular
physiological context. These observations illustrate the complex-
ity of the cellular and molecular mechanisms by which innate
immunity can inﬂuence alloimmunity toward rejection or tol-
erance. Further dissection of the innate immune response will
be required to grasp some of this complexity, at least enough
to be able to manipulate this type of immune response to our
advantage.
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